M&A Deal Summary |
|
|---|---|
| Date | 2023-02-28 |
| Target | Catalyst Biosciences - Rare Disease Pipeline in Hematology |
| Sector | Life Science |
| Buyer(s) | GC Biopharma |
| Sellers(s) | Catalyst Biosciences |
| Deal Type | Divestiture |
SEARCH BY
GC Biopharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. GC Biopharma is based in Gyeonggi-do, South Korea.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Life Science |
Catalyst Biosciences, Inc. is a privately held biotechnology company focused on engineering and developing novel therapeutic protease products.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-24 |
Catalyst Biosciences - Protease Medicines
San Francisco, California, United States Catalyst Biosciences' Protease Medicines that regulate complement, including CB 2782-PEG. Catalyst Biosciences' Protease Medicines is based in San Francisco, California. |
Sell | $60M |
